Although ROCK has been linked to podoplanin-mediated migration, conflicting findings have reported increased (Wicki et al., 2006; Petrie et al., 2012) and decreased (Suchanski et al., 2017; Neri et al., 2015) levels of migration in cancer-associated MSC lines treated with ROCK-blocking agents. The gene discussed is PDPN; the disease is cancer.